May 31, 2020
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
May 05, 2020
Jupiter Orphan Therapeutics, Inc. Strengthens its Advisory Positions
Apr 29, 2020
BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
Apr 06, 2020
BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe
Feb 20, 2020
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
Jan 30, 2020
Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
Jan 02, 2020
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Dec 23, 2019
BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
Dec 23, 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Nov 21, 2019
BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Nov 14, 2019
Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York
Nov 14, 2019
BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study
Oct 23, 2019
BioMarin Announces Third Quarter 2019 Financial Results
Sep 26, 2019
BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU
Aug 01, 2019
BioMarin Announces Second Quarter 2019 Financial Results
Jul 08, 2019
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
Jun 26, 2019
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019
May 30, 2019
Elastomeric Infusion Pumps Market is Expected to Reach Approximately US$ 2,100 Mn in Terms of Value by the End of 2030 - Persistence Market Research
May 28, 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
Apr 25, 2019
BioMarin Announces First Quarter 2019 Financial Results